ALSO NOTED: Neose restructures, sells facility; Warner Chilcott announces IPO terms; and much more...

> Neose Technologies plans to sell its plant and headquarters facility in Horsham, PA for about $21 million and lay off a quarter of its workforce. The drug developer plans to spend $3.5 million on new lab and office space. Report

> Warner Chilcott says it now plans to raise $1.3 billion in an IPO. The asking price for 70.6 million shares is an expected $17 to $19 each. Report

> Auxilium Pharmaceuticals has paid $1.8 million to Oscient Pharmaceuticals to terminate their deal to co-promote Testim for low testosterone. Auxilium has also leased a facility to produce an experimental therapy for Dupuytren's Contracture. Report

> GW Pharmaceuticals has launched a new effort to gain approvals for its pain drug Sativex in Europe. Report

> Israel's Pharmos has revised its acquisition deal with Vela Pharmaceuticals. Report

> Chutes & Ladders: InNexus Biotechnology has named Jeff Morhet as its new CEO and president. Release

> Salix Pharmaceuticals and the Debiopharm Group signed an exclusive license agreement granting Salix the right to sell, market and distribute SANVAR IR in the United States. Debiopharm developed SANVAR for the treatment of acute esophageal variceal bleeding. Release

> Roche is appealing a recent negative opinion from the CHMP in Europe for Tarceva as a therapy for pancreatic cancer. Report

> A researcher has provided an upbeat assessment of GSK's Advair for COPD to the European Respiratory Society in Munich. Report

And Finally… Men who wait to father children until after they turn 40 run a significantly elevated risk of having autistic children. Article

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.